| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -10,238,000 | -21,664,000 | -16,238,450 | -5,416,550 |
| Accretion of interest for royalty obligations | 1,077,000 | 1,081,000 | 1,316,000 | NaN |
| Change in fair value of convertible notes | 5,203,000 | -14,984,000 | NaN | NaN |
| Depreciation of property and equipment | 469,000 | 340,000 | 389,000 | NaN |
| Amortization of intangible assets | 1,031,000 | 877,000 | 679,000 | NaN |
| Accounts payable and accrued expenses | NaN | NaN | NaN | 3,102,476 |
| Impairment of intangible assets | NaN | 285,000 | NaN | NaN |
| Amortization of debt discount | 195,000 | 0 | 109 | 258,891 |
| Lease amortization expense | NaN | NaN | 74,000 | NaN |
| Lease amortization expense | 70,000 | -169,000 | 243,000 | NaN |
| Stock-based compensation | 1,908,000 | 1,799,000 | 2,762,683 | 899,317 |
| Inventory write-off | NaN | 263,000 | 792,000 | NaN |
| Gain on default judgment | NaN | 0 | NaN | NaN |
| Accounts receivable | 2,842,000 | 870,000 | 7,940,000 | NaN |
| Inventory | -156,000 | -393,000 | -1,385,000 | NaN |
| Prepaid expenses | -498,000 | -531,000 | 1,463,959 | -52,959 |
| Operating lease right-of-use assets | -104,000 | -345,000 | NaN | NaN |
| Accounts payable | 3,161,000 | -2,675,000 | 4,031,000 | NaN |
| Accrued expenses | -1,908,000 | 3,474,000 | 2,665,364 | 23,636 |
| Contingent consideration | -1,200,000 | 2,200,000 | NaN | NaN |
| Operating lease liabilities | -163,000 | -93,000 | -189,000 | NaN |
| Deferred revenue | -241,000 | -883,000 | 294,000 | NaN |
| Deferred income tax | NaN | 7,852,000 | -465,000 | NaN |
| Due from chromocell corporation | NaN | NaN | NaN | 0 |
| Other assets and liabilities | NaN | 62,000 | -97,000 | NaN |
| Net cash used in operating activities | -13,126,000 | -6,252,000 | -15,258,729 | -1,079,271 |
| Purchases of property and equipment | 194,000 | 99,000 | NaN | NaN |
| Assets acquisition-Xepi Acquisition | NaN | 6,080,000 | NaN | NaN |
| Assets acquisition-XEGLYZEAsset Purchase Agreement | NaN | 1,818,000 | NaN | NaN |
| Acquisition of lnhc, inc | NaN | 5,522,000 | -2,761,000 | NaN |
| Net cash used in investing activities | -194,000 | -7,997,000 | 2,761,000 | NaN |
| Payment of loan payable, net of debt discount | NaN | NaN | -845,000 | 0 |
| Proceeds from pipe, net | NaN | 0 | 27,384,000 | NaN |
| Proceeds from loan payable, net of debt discount - related party | NaN | NaN | NaN | 0 |
| Payment of loan payable, net of debt discount | NaN | 845,000 | NaN | NaN |
| Proceeds from stock option exercises | NaN | 121,000 | 85,000 | NaN |
| Common stock issued for cash | NaN | 0 | NaN | 0 |
| Proceeds from convertible note | NaN | 17,898,000 | NaN | NaN |
| Proceeds from venture loan and security agreement, net | 29,337,000 | NaN | NaN | NaN |
| Rescission of common stock | NaN | 0 | NaN | NaN |
| Proceeds from loan payable, net of debt discount | 0 | 0 | 68,000 | 625,000 |
| Repurchase of common stock under stock repurchase plan | NaN | 0 | NaN | NaN |
| Recission of common stock | NaN | NaN | NaN | 0 |
| Shares issued for cash under equity line of credit | NaN | 0 | NaN | NaN |
| Payment of venture loan and security agreement issuance costs | 1,814,000 | NaN | NaN | NaN |
| Net cash provided by financing activities | 27,523,000 | 18,019,000 | 26,692,000 | 625,000 |
| Net increase in cash and cash equivalents | 14,203,000 | 3,770,000 | 14,194,271 | -454,271 |
| Cash and cash equivalents at beginning of period | NaN | NaN | 513,000 | NaN |
| Cash, cash equivalents and restricted cash as of beginning of period | 18,023,000 | 14,253,000 | NaN | NaN |
| Cash and cash equivalents at end of period | NaN | NaN | 14,253,000 | NaN |
| Cash, cash equivalents and restricted cash as of end of period | 32,226,000 | 18,023,000 | NaN | NaN |
Pelthos Therapeutics Inc. (PTHS)
Pelthos Therapeutics Inc. (PTHS)